Drug Profile
Research programme: diabetes therapeutics - NGM Biopharmaceuticals/Johnson & Johnson Innovative Medicine
Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator NGM Biopharmaceuticals
- Developer Johnson & Johnson Innovative Medicine; NGM Biopharmaceuticals
- Class Proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in USA
- 03 Jan 2013 Early research in Type-2 diabetes mellitus in USA (unspecified route)